Investments & digital assets › F8949.D.X133
F8949.D.X133 · federal · F8949 line D.X133
Delmar Pharma (acquired 2023-07-13, sold 2025-02-11; proceeds 1,154.90, basis 1,362.58)
-207.68
engine v3
not yet verified
How this number was built
R-8949-LOT One line per sale: proceeds minus basis plus adjustment. Broker basis is used as reported unless a supplemental statement for the same lot is matched.
Sources (6) — where the inputs came from
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 4 · field X133_desc · “Lot X133 description”
read as “Delmar Pharma” → Delmar Pharma
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 4 · field X133_acq · “Lot X133 date acquired”
read as “07/13/2023” → 2023-07-13
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 4 · field X133_sold · “Lot X133 date sold”
read as “02/11/2025” → 2025-02-11
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 4 · field X133_proceeds · “Lot X133 proceeds”
read as “1,154.90” → 1,154.90
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 4 · field X133_basis · “Lot X133 cost basis”
read as “1,362.58” → 1,362.58
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 4 · field X133_wash · “Lot X133 wash sale loss disallowed”
read as “0.00” → 0
99%
Flows into
History — nothing is overwritten
v1 · 2026-03-04: -207.68v2 · 2026-03-19: -207.68v3 · 2026-06-23: -207.68
Adjust this number
Evidence & discussion
Record how you verified it